Today it was reported that the CEO of BioMarin Pharmaceutical Inc. (BMRN), Jean Jacques Bienaime, exercised options to buy 1,000 BMRN shares at $21.51 a share, for a total transaction value of $21.51K.
See today’s analyst top recommended stocks >>
Currently, BioMarin Pharmaceutical Inc. has an average volume of 2.07M.
Based on 12 analyst ratings, the analyst consensus is Strong Buy with an average price target of $115.00, reflecting a 38.3% upside. Nine different firms, including Cantor Fitzgerald and Cowen & Co., currently also have a Buy rating on the stock. Starting in March 2019, BMRN received 7 Buy ratings in a row.
The insider sentiment on BioMarin Pharmaceutical Inc. has been positive according to 135 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its products include Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim.
Read More on BMRN:
